Actelion's Selexipag for pulmonary arterial hypertension lowers mortality risks during Phase III study Actelion's experimental drug selexipag for the treatment of pulmonary arterial hypertension shows promising result in the phase III study GRIPHON, which involved over 1,000 PAH patients from 39 countries. by Rhodi Lee
Xi Jinping Warns Against Chip Restrictions During Talks with Dutch PM Rutte: 'No Force Can Stop China's Progress'
Researchers Achieve Record Data Transmission Speed, 4.5 Million Times Faster Than Average Home Broadband